Deerfield Management Company, L.P. (Series C) Ventyx Biosciences, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 6,715,501 shares of VTYX stock, worth $15.1 Million. This represents 0.27% of its overall portfolio holdings.
Number of Shares
6,715,501
Previous 5,829,570
15.2%
Holding current value
$15.1 Million
Previous $13.5 Million
8.71%
% of portfolio
0.27%
Previous 0.28%
Shares
4 transactions
Others Institutions Holding VTYX
# of Institutions
125Shares Held
52.9MCall Options Held
35.3KPut Options Held
83K-
Black Rock Inc. New York, NY4.77MShares$10.7 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.46MShares$10 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$7.8 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.17MShares$7.13 Million0.03% of portfolio
-
Tang Capital Management LLC San Diego, CA3.1MShares$6.98 Million0.58% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $127M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...